Othera Initiates Dosing in Phase I/II Ocular Hypertension and Glaucoma Study
Othera Pharmaceuticals, a specialty pharmaceutical company, has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma.
The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75% OT-730, 0.5% timolol maleate or placebo.
According to Othera, OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intraocular pressure, the risk factor for developing glaucoma.
David Joseph, CEO and chairman of Othera, said: “Our compound’s unique chemistry enables a clinical development plan emphasizing improved safety, and provides the support needed for OT-730 to be a successful product in a growing, age-related market.”